Regulatory PathRegulatory requirements compared

Active substance

Nortriptyline

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
AVENTYL CAPSULES 10 MG10 mgCapsule · Oral use100 Tablet ContainerSAR 13.35NCE · PrescriptionEli Lilly and CompanyWithdrawn by MAH · Not Marketed
AVENTYL CAPSULES 10 MG10 mgCapsule · Oral use25 Tablet ContainerSAR 3.60NCE · PrescriptionEli Lilly and CompanyWithdrawn by MAH · Not Marketed
AVENTYL CAPSULES 25 MG25 mgCapsule · Oral use100 Tablet ContainerSAR 17.35NCE · PrescriptionEli Lilly and CompanyWithdrawn by MAH · Not Marketed
AVENTYL CAPSULES 25 MG25 mgCapsule · Oral use25 Tablet ContainerSAR 6.30NCE · PrescriptionEli Lilly and CompanyWithdrawn by MAH · Not Marketed
NORTRILEN TAB. 25 MG.25 mgTablet · Oral use100 Tablet ContainerSAR 41.20Generic · PrescriptionH. LUNDBECKWithdrawn by MAH · Not Marketed
NORTRILEN TAB. 25 MG.25 mgTablet · Oral use50 Tablet ContainerSAR 15.45Generic · PrescriptionH. LUNDBECKWithdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
NORTRIPTYLINE HYDROCHLORIDEEQ 75MG BASE; EQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASEcapsule · oralDR REDDYS LABS SAPrescription30 Mar 1992
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 75MG BASEcapsule · oralTEVAPrescription27 Mar 1995
NORTRIPTYLINE HYDROCHLORIDEEQ 50MG BASE; EQ 75MG BASE; EQ 25MG BASE; EQ 10MG BASEcapsule · oralTAROPrescription8 May 2000
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE/5MLsolution · oralPHARM ASSOCPrescription23 Aug 2000
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE/5MLsolution · oralRUBICON RESEARCHPrescription15 Aug 2023
AVENTYL HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASEcapsule · oralLILLYDiscontinued6 Nov 1964
AVENTYLEQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**solution · oralRANBAXYDiscontinued6 Nov 1964
PAMELOREQ 10MG BASE/5MLsolution · oralSPECGX LLCDiscontinued1 Aug 1977
PAMELOREQ 10MG BASE; EQ 25MG BASE; EQ 75MG BASE; EQ 50MG BASEcapsule · oralSPECGX LLCDiscontinued1 Aug 1977
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 75MG BASEcapsule · oralANI PHARMSDiscontinued31 Dec 1992
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 75MG BASEcapsule · oralRISINGDiscontinued26 Jul 1993
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 75MG BASEcapsule · oralTEVADiscontinued11 Apr 1996
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 75MG BASEcapsule · oralAUROBINDO PHARMA LTDDiscontinued30 Jun 1997
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE/5MLsolution · oralTARODiscontinued20 Jun 2006
NORTRIPTYLINE HYDROCHLORIDEEQ 10MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 75MG BASEcapsule · oralZYDUS LIFESCIENCESDiscontinued24 Feb 2021

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
AVENTYL0001522910 MGCAPSULE · ORALAA PHARMA INC
AVENTYL0001523725 MGCAPSULE · ORALAA PHARMA INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACNORTRIPTYLINE 10 MG/5 ML SOLN$0.26165per ML23 Sep 2026
US NADACNORTRIPTYLINE HCL 10 MG CAP$0.11272per EA23 Sep 2026
US NADACNORTRIPTYLINE HCL 25 MG CAP$0.15607per EA23 Sep 2026
US NADACNORTRIPTYLINE HCL 50 MG CAP$0.20739per EA23 Sep 2026
US NADACNORTRIPTYLINE HCL 75 MG CAP$0.27241per EA23 Sep 2026
NHS Drug TariffNortriptyline 10mg capsules£14.44100 capsule1 Oct 2026
NHS Drug TariffNortriptyline 10mg tablets£2.64100 tablet1 Oct 2026
NHS Drug TariffNortriptyline 25mg capsules£17.50100 capsule1 Oct 2026
NHS Drug TariffNortriptyline 25mg tablets£2.29100 tablet1 Oct 2026
NHS Drug TariffNortriptyline 50mg tablets£55.7830 tablet1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

All safety entries for nortriptyline →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.